General Information of the m6A Target Gene (ID: M6ATAR00737)
Target Name TGF-beta receptor type-2 (TGF-Beta-R2)
Synonyms
TGFR-2; TGF-beta type II receptor; Transforming growth factor-beta receptor type II; TGF-beta receptor type II; TbetaR-II
    Click to Show/Hide
Gene Name TGF-Beta-R2
Chromosomal Location 3p24.1
Family Protein kinase superfamily, TKL Ser/Thr protein kinase family, TGFB receptor subfamily
Function
Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and thus regulates a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways; [Isoform 1]: Has transforming growth factor beta-activated receptor activity; FUNCTION: [Isoform 2]: Has transforming growth factor beta-activated receptor activity; [Isoform 3]: Binds TGFB1, TGFB2 and TGFB3 in the picomolar affinity range without the participation of additional receptors. Blocks activation of SMAD2 and SMAD3 by TGFB1..
    Click to Show/Hide
Gene ID 7048
Uniprot ID
TGFR2_HUMAN
HGNC ID
HGNC:11773
Ensembl Gene ID
ENSG00000163513
KEGG ID
hsa:7048
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
TGF-Beta-R2 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
RNA demethylase ALKBH5 (ALKBH5) [ERASER]
Representative RNA-seq result indicating the expression of this target gene regulated by ALKBH5
Cell Line NOMO-1 cell line Homo sapiens
Treatment: shALKBH5 NOMO-1 cells
Control: shNS NOMO-1 cells
GSE144968
Regulation
logFC: -1.61E+00
p-value: 9.99E-05
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary ALKBH5 weakens YTHDF1/3-mediated TGF-beta receptor type-2 (TGF-Beta-R2) and SMAD3 mRNA stabilization, and abolishes YTHDF2-mediated SMAD6 mRNA degradation, supporting the notion that ALKBH5 inhibits TGF-Beta-induced EMT and invasion of NSCLC cells via YTHD1/2/3-mediated mechanism.
Target Regulation Down regulation
Responsed Disease Non-small-cell lung carcinoma ICD-11: 2C25.Y
Pathway Response TGF-beta signaling pathway hsa04350
Cell Process Epithelial-mesenchymal transition
In-vitro Model HEK293T Normal Homo sapiens CVCL_0063
NCI-H1650 Minimally invasive lung adenocarcinoma Homo sapiens CVCL_1483
A-549 Lung adenocarcinoma Homo sapiens CVCL_0023
In-vivo Model The mice were divided into control group and ALKBH5-overexpressing group (9 mice per group). ALKBH5-overexpressing and control A549 cells (3 × 106 cells/mouse) in 200 uL PBS were intravenously (i.v.) injected into the lateral tail vein of mice. At every 5th day post-inoculation, TGF-Beta-1 (4 ug/kg body weight) was intraperitoneally (i.p.) injected to promote tumor cell metastasis. Eight weeks later, the mice were euthanized, and then their lungs and livers were taken out and fixed in Bouin's solution (Sigma Aldrich, HT101128) or 4% Paraformaldehyde (Beyotime, p0099, Shanghai, China) for macroscopically metastatic nodule analysis.
Lung cancer [ICD-11: 2C25]
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary ALKBH5 weakens YTHDF1/3-mediated TGF-beta receptor type-2 (TGF-Beta-R2) and SMAD3 mRNA stabilization, and abolishes YTHDF2-mediated SMAD6 mRNA degradation, supporting the notion that ALKBH5 inhibits TGF-Beta-induced EMT and invasion of NSCLC cells via YTHD1/2/3-mediated mechanism.
Responsed Disease Non-small-cell lung carcinoma [ICD-11: 2C25.Y]
Target Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
Target Regulation Down regulation
Pathway Response TGF-beta signaling pathway hsa04350
Cell Process Epithelial-mesenchymal transition
In-vitro Model HEK293T Normal Homo sapiens CVCL_0063
NCI-H1650 Minimally invasive lung adenocarcinoma Homo sapiens CVCL_1483
A-549 Lung adenocarcinoma Homo sapiens CVCL_0023
In-vivo Model The mice were divided into control group and ALKBH5-overexpressing group (9 mice per group). ALKBH5-overexpressing and control A549 cells (3 × 106 cells/mouse) in 200 uL PBS were intravenously (i.v.) injected into the lateral tail vein of mice. At every 5th day post-inoculation, TGF-Beta-1 (4 ug/kg body weight) was intraperitoneally (i.p.) injected to promote tumor cell metastasis. Eight weeks later, the mice were euthanized, and then their lungs and livers were taken out and fixed in Bouin's solution (Sigma Aldrich, HT101128) or 4% Paraformaldehyde (Beyotime, p0099, Shanghai, China) for macroscopically metastatic nodule analysis.
References
Ref 1 RNA demethylase ALKBH5 inhibits TGF-Beta-induced EMT by regulating TGF-Beta/SMAD signaling in non-small cell lung?cancer. FASEB J. 2022 May;36(5):e22283. doi: 10.1096/fj.202200005RR.